{"date":"2026-02-27","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6446-2026-02-27-2036-m3g66l","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2026-02-27","time":"20:36:34","subject":"本公司代子公司PharmaEssentia Korea Corp.公告於韓國申請新藥BESREMi（Ropeginterferon alfa-2b）新增適應症，新增適應症為原發性血小板過多症（ET）","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2026-02-27 20:36，「本公司代子公司PharmaEssentia Korea Corp.公告於韓國申請新藥BESREMi（Ropeginter」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}